Close Menu

Tekmira

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week announced that it has received a $1.5 million milestone payment from ag-bio firm Monsanto under the terms of a technology-licensing deal.

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals said this week that it has been notified that the US Food and Drug Administration has placed a hold on a Phase I study of the company's siRNA-based Ebola virus drug, TKM-Ebola.

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals last week announced its control of a US patent, acquired through its purchase of Merck's RNAi drug assets earlier this year, that it says is a necessary piece of intellectual property for any group looking to develop an siRNA-based treatment for hepa

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week announced that it is beginning a Phase I/II trial of its cancer drug TKM-PLK1 in patients with hepatocellular carcinoma (HCC).

NEW YORK (GenomeWeb) – Amid increasing competition in the hepatitis B field among RNAi drug developers, Tekmira Pharmaceuticals remains on track to begin clinical testing of its HBV therapy early next year, the company's top official said last week.

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week announced that it has completed the single ascending dose portion of a Phase I trial of its RNAi-based Ebola treatment TKM-Ebola, with treatment proving to be well tolerated up to .3 mg/kg.

Title: Lipids and Compositions for the Delivery of Therapeutics
Patent Number: 8,722,082
Filed: Nov. 10, 2009

NEW YORK (GenomeWeb) – Amid a recent downturn among biotechnology stocks, shares of the top eight publicly traded RNAi and microRNA drug developers have fared particularly poorly, shedding an average of 37 percent of their value from their year-to-date highs.

Tekmira Pharmaceuticals this week announced the release of new preclinical data showing that the company's RNAi-based Marburg virus drug could prevent death in non-human primates infected with a lethal dose of the pathogen.

As it eyes new opportunities for its delivery technology, Tekmira Pharmaceuticals is exploring the potential of its lipid nanoparticles (LNPs) as carriers for messenger RNA therapeutics, the company's top official said last week.

Pages

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.